Eric H. Kraut

4.2k total citations
107 papers, 2.5k citations indexed

About

Eric H. Kraut is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Eric H. Kraut has authored 107 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 35 papers in Genetics and 34 papers in Hematology. Recurrent topics in Eric H. Kraut's work include Chronic Lymphocytic Leukemia Research (20 papers), Cancer therapeutics and mechanisms (17 papers) and Cancer Treatment and Pharmacology (13 papers). Eric H. Kraut is often cited by papers focused on Chronic Lymphocytic Leukemia Research (20 papers), Cancer therapeutics and mechanisms (17 papers) and Cancer Treatment and Pharmacology (13 papers). Eric H. Kraut collaborates with scholars based in United States, Canada and Netherlands. Eric H. Kraut's co-authors include Michael R. Grever, Michael R. Grever, Bertha A. Bouroncle, Spero R. Cataland, Donn C. Young, James A. Neidhart, Earl N. Metz, Kenneth K. Chan, Haifeng Wu and Stanley P. Balcerzak and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Eric H. Kraut

105 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric H. Kraut United States 29 808 793 778 719 520 107 2.5k
Ronald L. Dubowy United States 26 589 0.7× 701 0.9× 1.0k 1.3× 453 0.6× 244 0.5× 67 2.3k
Jacques‐Olivier Bay France 25 891 1.1× 702 0.9× 386 0.5× 721 1.0× 391 0.8× 151 2.4k
Louis F. Diehl United States 27 429 0.5× 412 0.5× 1.0k 1.3× 630 0.9× 596 1.1× 85 2.3k
Jan Liliemark Sweden 31 792 1.0× 998 1.3× 1.5k 1.9× 992 1.4× 467 0.9× 113 3.2k
Elliott F. Winton United States 23 1.4k 1.7× 841 1.1× 1.2k 1.6× 454 0.6× 254 0.5× 81 2.5k
Leif Stenke Sweden 28 2.1k 2.6× 668 0.8× 1.3k 1.6× 847 1.2× 506 1.0× 113 3.2k
Roger Chen United States 13 1.2k 1.5× 1.1k 1.4× 402 0.5× 767 1.1× 496 1.0× 26 2.3k
José F. Leis United States 31 1.3k 1.6× 690 0.9× 1.6k 2.1× 776 1.1× 820 1.6× 159 3.2k
Sikander Ailawadhi United States 28 1.7k 2.1× 1.1k 1.4× 620 0.8× 1.4k 2.0× 301 0.6× 312 3.1k
Anna Marina Liberati Italy 31 1.3k 1.6× 1.1k 1.4× 689 0.9× 1.9k 2.7× 310 0.6× 148 3.8k

Countries citing papers authored by Eric H. Kraut

Since Specialization
Citations

This map shows the geographic impact of Eric H. Kraut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric H. Kraut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric H. Kraut more than expected).

Fields of papers citing papers by Eric H. Kraut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric H. Kraut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric H. Kraut. The network helps show where Eric H. Kraut may publish in the future.

Co-authorship network of co-authors of Eric H. Kraut

This figure shows the co-authorship network connecting the top 25 collaborators of Eric H. Kraut. A scholar is included among the top collaborators of Eric H. Kraut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric H. Kraut. Eric H. Kraut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anghelina, Mirela, Michelle J. Naughton, Qiuhong Zhao, et al.. (2022). Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia. Leukemia Research. 120. 106919–106919. 1 indexed citations
2.
Cuker, Adam, Miguel A. Escobar, M. Elaine Eyster, et al.. (2022). Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis. 20(4). 857–865. 21 indexed citations
3.
Huang, Ying, et al.. (2021). Myocardial injury and coronary microvascular disease in sickle cell disease. Haematologica. 106(7). 2018–2021. 6 indexed citations
4.
Li, Junan, et al.. (2020). Trends in anticoagulation management services following incorporation of direct oral anticoagulants at a large academic medical center. Journal of Thrombosis and Thrombolysis. 51(4). 1050–1058. 2 indexed citations
5.
Rodgers, George M., Pamela S. Becker, Morey A. Blinder, et al.. (2012). Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 10(5). 628–653. 171 indexed citations
6.
7.
Crawford, Brooke, et al.. (2009). Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer. Cancer Investigation. 27(10). 984–988. 10 indexed citations
8.
Cataland, Spero R., Ming Jin, Shili Lin, et al.. (2008). Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. American Journal of Hematology. 83(12). 911–915. 28 indexed citations
9.
Mauer, Ann M., Eric H. Kraut, S Krauß, et al.. (2005). Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Annals of Oncology. 16(8). 1320–1325. 48 indexed citations
10.
Kuebler, J. Philip, et al.. (2004). Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma. Investigational New Drugs. 22(2). 181–184. 2 indexed citations
11.
Grever, Michael R., Charles A. Doan, & Eric H. Kraut. (2003). Pentostatin in the treatment of hairy-cell leukemia. Best Practice & Research Clinical Haematology. 16(1). 91–99. 18 indexed citations
12.
Moore, Timothy D., et al.. (2002). A Phase II Study of CI-980 in Previously Untreated Extensive Small Cell Lung Cancer: An Ohio State University Phase II Research Consortium Study. Cancer Investigation. 20(2). 192–198. 11 indexed citations
13.
Kraut, Eric H., Stanley P. Balcerzak, Donn C. Young, Mellar P. Davis, & Samuel A. Jacobs. (2002). A Phase II Study of Topotecan in Non-Hodgkin's Lymphoma: An Ohio State University Phase II Research Consortium Study. Cancer Investigation. 20(2). 174–179. 8 indexed citations
14.
Saad, Everardo D., Eric H. Kraut, Paulo M. Hoff, et al.. (2002). Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. American Journal of Clinical Oncology. 25(5). 451–453. 48 indexed citations
15.
Liu, Jing, Eric H. Kraut, Rebecca Brooks, et al.. (2002). Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemotherapy and Pharmacology. 49(5). 367–374. 23 indexed citations
16.
Kuebler, J. Philip, Gerald W. King, Pierre L. Triozzi, Timothy D. Moore, & Eric H. Kraut. (2001). Phase II Study of Pyrazoloacridine in Metastatic Renal Cell Carcinoma. Investigational New Drugs. 19(4). 327–328. 6 indexed citations
17.
Kraut, Eric H., Thomas R. Fleming, John S. Macdonald, et al.. (1993). Phase II Trial of Merbarone in Pancreatic Carcinoma. American Journal of Clinical Oncology. 16(4). 327–328. 8 indexed citations
18.
Grever, Michael R., et al.. (1992). A phase II investigation of pentostatin in metastatic malignant melanoma. Investigational New Drugs. 10(4). 345–346. 1 indexed citations
19.
Kraut, Eric H., T Fleming, Michal Segal, et al.. (1991). Phase II study of pibenzimol in pancreatic cancer. Investigational New Drugs. 9(1). 95–96. 32 indexed citations
20.
Kraut, Eric H., et al.. (1990). Phase II study of Fludarabine Phosphate in multiple myeloma. Investigational New Drugs. 8(2). 199–200. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald L. Dubowy Breakdown of academic impact, for papers by Jacques‐Olivier Bay Breakdown of academic impact, for papers by Louis F. Diehl Breakdown of academic impact, for papers by Jan Liliemark Breakdown of academic impact, for papers by Elliott F. Winton Breakdown of academic impact, for papers by Leif Stenke Breakdown of academic impact, for papers by Roger Chen Breakdown of academic impact, for papers by José F. Leis Breakdown of academic impact, for papers by Sikander Ailawadhi Breakdown of academic impact, for papers by Anna Marina Liberati
Rankless by CCL
2026